BTAI vs. VACC, MRNS, BRNS, QTTB, CMRX, SPRO, ONCY, CNTB, PRPH, and CRVS
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Vaccitech (VACC), Marinus Pharmaceuticals (MRNS), Barinthus Biotherapeutics (BRNS), Q32 Bio (QTTB), Chimerix (CMRX), Spero Therapeutics (SPRO), Oncolytics Biotech (ONCY), Connect Biopharma (CNTB), ProPhase Labs (PRPH), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
Vaccitech has higher revenue and earnings than BioXcel Therapeutics. Vaccitech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vaccitech has a net margin of -409.18% compared to BioXcel Therapeutics' net margin of -8,715.72%. Vaccitech's return on equity of -23.41% beat BioXcel Therapeutics' return on equity.
In the previous week, BioXcel Therapeutics had 15 more articles in the media than Vaccitech. MarketBeat recorded 15 mentions for BioXcel Therapeutics and 0 mentions for Vaccitech. BioXcel Therapeutics' average media sentiment score of 0.06 beat Vaccitech's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media.
BioXcel Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500.
BioXcel Therapeutics received 221 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 35.8% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 6.0% of Vaccitech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioXcel Therapeutics presently has a consensus target price of $16.71, indicating a potential upside of 699.73%. Vaccitech has a consensus target price of $7.63, indicating a potential upside of 226.55%. Given BioXcel Therapeutics' higher possible upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Vaccitech.
Summary
BioXcel Therapeutics beats Vaccitech on 10 of the 18 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
